Avalo Therapeutics, Inc. is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. Co.'s lead asset is AVTX-009, an anti-IL-1? mAb, targeting inflammatory diseases. Its pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein). AVTX-009 is a humanized monoclonal antibody (IgG4) that binds to interleukin-1? (IL-1?) with high affinity and neutralizes its activity. IL- 1? is a central driver in the inflammatory process. We show 17 historical shares outstanding datapoints in our AVTX shares outstanding history coverage, used to compute AVTX market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing AVTX market cap history over the course of time is important for investors
interested in comparing AVTX's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of AVTX versus a peer is one thing; comparing
AVTX market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like AVTX can fluctuate over the course of history.
With this page we aim to empower investors researching AVTX by allowing them to research the AVTX market cap history. |
Free AVTX Email Alerts:
Video: The Importance of Market Cap
